Organigram Announces Agreement to Acquire Aurora Cannabis

Organigram (TSE:OGI) agreed to acquire Aurora Cannabis for approximately C$561 million. Organigram secured C$210 million in credit facilities and a £99.9 million investment from BAT. Analysts have mixed views on OGI, with a Buy rating and C$3.00 target, while TipRanks' AI rates it Neutral.

Original reporting
Published Nov 13, 2026, 11:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$ACB
Bullish
high confidence
Mentioned
$ACB · $OGI
Relevance
8/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$ACBBullishMed
01

Why it matters

The transaction represents a significant consolidation in the cannabis industry, providing a cash exit for Aurora shareholders while increasing Organigram's debt load and share count.

02

Market read

The deal is material for cannabis sector investors and may trigger re‑pricing of related stocks.

03

What to watch

Regulatory approvals and integration costs could delay benefits, and the new credit facility adds leverage risk to Organigram.

Relevance 8/10Novelty 8/10Timing: immediate

Background

Organigram Global (TSX:OGI) and Aurora Cannabis (NYSE:ACB) disclosed a definitive acquisition agreement, valued at C$561 million, with accompanying senior secured credit facilities and a private placement by BAT.

Company-level read

Ticker impact

$ACBBullishHigh confidence
Context

Aurora Cannabis shareholders will receive cash for all outstanding shares as part of the C$561 million acquisition by Organigram.

Expected impact

likely upside for ACB as the market prices in the cash offer

Evidence & confidence

A cash‑out transaction at a premium generally lifts the target's share price on announcement.

Market effects

The deal consolidates the Canadian cannabis sector, potentially reducing competition and prompting re‑valuation of peers.

Canadian cannabis market may see tighter supply dynamics, affecting other TSX‑listed growers.

Limited to cannabis investors; no broader macro impact.

Counterpoint

If the acquisition price is deemed too low, Aurora shareholders might resist, causing deal risk and possible price volatility.

Key entities

  • Organigram Global

    Acquirer, Canadian cannabis producer.

  • Aurora Cannabis

    Target, Canadian cannabis producer.

  • ATB Financial

    Provider of senior secured credit facilities.

  • BAT

    Private placement investor.

Related articles

$CURLFHighAI 8/10

Curaleaf Holdings, Inc. Investor Relations Curaleaf Receives All Required Competition Law Clearances for Proposed Acquisition of Aurora Cannabis

Curaleaf Holdings, Inc. (CURLF) filed an SEC Form 8-K — Other Events. Curaleaf Holdings, Inc. Investor Relations Curaleaf Receives All Required Competition Law Clearances for Proposed Acquisition of Aurora Cannabis STAMFORD, Conn., Nov. 10, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (the "Company"), a leading internatio

$CURLFHighAI 8/10

Curaleaf reports competition clearances for Aurora bid

Curaleaf Holdings received competition clearances from Canada and Germany for its bid to acquire Aurora Cannabis. The offer, expiring Dec. 4, faces competition from a rival bid by Organigram, which Aurora's board supports. Curaleaf's offer includes cash and shares, while Organigram's is all-share. Both bids cite potential synergies and international scale.